Robust Q1 Performance

Novonesis, the parent company of NSIS-B.CO stock, reported strong financial results for the first quarter of 2026. The company delivered 7% organic sales growth, exceeding expectations, and achieved an adjusted EBITDA margin of 37.8%. This growth was driven by all sales areas and regions, with both Developed and Emerging markets contributing to the increase. The Food & Health Biosolutions segment grew 9% organically, while Planetary Health Biosolutions experienced 5% organic growth. Developed Markets saw an 8% increase in organic sales, while Emerging Markets reported a 4% growth rate, both including the effect of exiting certain countries. Novonesis also announced a successful bond issuance of EUR 1.7 billion to refinance a bridge loan facility. The company confirmed its full-year outlook, expecting organic sales growth between 5‑7%, with an adjusted EBITDA margin range of 37‑38%. Novonesis’s financial performance and strategic initiatives position the company for continued success, driven by growing demand for biosolutions.